In 2019, elexacaftor-tezacaftor-ivacaftor (Trikafta), the combination of two CFTR correctors, VX-445 (elexacaftor) and VX-661 (tezacaftor) with the CFTR potentiator VX-770 (ivacaftor), was approved for clinical use in people with CF carrying the F508del mutation on at least one allele (https://www.fda.gov/news-events/press-announcements/fda-approves-new-breakthrough-therapy-cystic-fibrosis), following very positive clinical trial results [25,26]. This evidence concerns the gene CFTR and cystic fibrosis.